Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 7.01
Katherine W. Brunelle was named Executive Vice President, Chief Credit Officer effective July 1, 2026, representing a material executive appointment to a senior leadership position. While Ryan A. Smith's transition to Executive Vice President, Commercial Banking is also disclosed, the primary action disclosed is Brunelle's appointment to the chief credit officer role, a key executive position at the bank holding company. The appointment of a senior executive with 20 years of commercial banking and credit experience to lead credit operations is material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of John M. Lutz, age 64, to ePlus's Board of Directors on July 6, 2026, increasing the board size from eight to nine directors. Mr. Lutz was also appointed to the Audit Committee and Compensation Committee. The Board determined he is an independent director under Nasdaq rules. This is a clear executive appointment event, material to investors as board composition and committee assignments affect governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
Steven Dorwart's appointment as President, Connectivity and Cloud Solutions effective immediately is the principal disclosed action. While Jason Phillips' retirement is also mentioned, the filing centers on the succession and appointment of Dorwart to a key executive role overseeing a major business segment. The press release emphasizes Dorwart's qualifications, experience, and strategic importance to the company's growth trajectory, making the appointment the salient event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Stephen R. Curley was appointed to the boards of Eagle Bancorp and its subsidiary EagleBank effective July 6, 2026, in connection with his previously announced position as President and Chief Executive Officer. The appointment of a CEO to the board is a material executive appointment that would affect a reasonable investor's assessment of the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Kyndryl appointed Ellen Johnson as Chief Financial Officer effective approximately August 6, 2026, and Andrew Bonzani as General Counsel and Secretary effective July 1, 2026. Both appointments include compensatory arrangements reflecting their senior leadership roles.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The exhibit announces the appointment of Rob Slack, PhD, as Chief Scientific Officer of Vicore Pharma, effective immediately. This is a material executive appointment at a clinical-stage biopharmaceutical company, where the Chief Scientific Officer role is critical to research strategy and pipeline development. The disclosure also notes that the prior CSO, Johan Raud, is transitioning to Senior Advisor, which is a secondary departure element but the primary disclosed action is Slack's appointment to the CSO position.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Five individuals—Professor Dr Sir Ralf Speth, Dr. John Llewellyn, Steven G. Osgood, Hideyuki Nakashima, and Steven Robert Armstrong—were appointed to the board of directors effective July 1, 2026 in connection with the IPO, with four designated as independent directors and committee assignments to the Audit and Compensation Committees.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-06
EX-99.1
Dylan Marx has been appointed as Chief Executive Officer of Recurrent Energy, the Company's global project development subsidiary, effective immediately. While Ismael Guerrero's departure from the CEO role is also disclosed, the principal action announced is the appointment of Marx to lead a material subsidiary. The filing emphasizes Marx's qualifications and the seamless transition plan, consistent with an executive appointment disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Hope Lundt was appointed to the Board of Directors of EWSB Bancorp, Inc. and its subsidiary on July 1, 2026, and assigned to the Audit Committee and Governance and Nominating Committee. This is a clear director appointment, the principal disclosed action. The disclosure of standard non-employee director compensation arrangements is incidental to the appointment itself.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The exhibit discloses the appointment of Yoav Har-Even as an independent director of Innoviz Technologies Ltd. effective July 5, 2026, to fill a newly vacant seat. This is a clear executive/governance appointment event. While the filing also mentions James Sheridan's resignation, the principal disclosed action is the appointment of a new director with significant qualifications (former CEO of Rafael Advanced Defense Systems, retired Major General). Board composition changes affecting independent director status are material to investors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 1.01
Corbus Pharmaceuticals appointed Leonardo Viana Nicacio, M.D. as Chief Medical Officer, effective August 3, 2026, under a two-year employment agreement. Dr. Nicacio brings 20+ years of pharmaceutical development experience, including pivotal work on TIVDAK®, and expertise in ADCs and HPV-driven oncology directly aligned with the company's strategic priorities as it approaches initiation of the TEMPO-1 registrational study. The appointment includes material inducement equity awards of $2.1 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Effective immediately prior to the spin-off consummation, Midera appointed a complete board of directors (8 members) and executive leadership team, including Mark M. Salman as CEO, Amy A. Campbell as CFO, Mark S. Bowie as COO, and Matthew R. Fuchsen as Chief Strategy Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
The filing discloses both a director resignation (Dr. Jovan-Embiricos) and the election of a new director (Laurie Keating to the Board and Audit Committee, effective August 1, 2026). While both events occur, the principal action emphasized in the disclosure is the appointment of Ms. Keating, including detailed compensation terms (18,000 option grant, $40,000 annual cash, $7,500 Audit Committee fee). Director appointments are material governance events affecting board composition and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
Item 5.02
The filing discloses two executive changes: Tamar Howson's resignation from the Board and Compensation Committee on June 29, 2026, and Erik Lundgren's appointment as a Class II director on July 5, 2026. While both events are disclosed, the principal action emphasized is Lundgren's appointment to the Board following the Nominating and Corporate Governance Committee's recommendation. The appointment of the CEO to the Board is the forward-looking material event, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
The filing discloses multiple executive appointments effective July 1, 2026: Charles Nelson as Chairman and CEO (promoted from President and COO), Ted Warner as President and director (promoted from CFO), and José Rodriguez as Chief Operating Officer (promoted from VP). While the section also includes an executive departure (E. Will Gray II's resignation as director and demotion from CEO to President, Permian), the principal disclosed actions center on the appointments and promotions of three executives to senior leadership roles, with corresponding employment agreement amendments and compensatory arrangements. These leadership changes are material to investors assessing the registrant's governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
Keel Infrastructure Corp. appointed Ganesh Aiyer as President, effective July 6, 2026, reporting directly to CEO Ben Gagnon. Aiyer brings 25 years of experience from senior roles at Digital Realty Trust, Schneider Electric, and Dell Technologies, and will be responsible for commercial strategy and pipeline expansion. The appointment includes compensatory arrangements comprising a $500,000 base salary, bonus plan eligibility, 100,000 stock options, $1.5M in RSUs, and severance provisions.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
On July 1, 2026, the Board appointed Ms. Sha, XIA as a Director of Grande Group Limited to fill the vacancy created by Mr. Ying Wo Sammy, HO's resignation on April 15, 2026. The filing discloses the appointment of a director, her employment agreement with an annual salary of HK$180,000, and her professional background. This is a clear executive appointment event material to investors assessing the company's leadership composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
The 6-K discloses the Board's resolution on July 3, 2026 to appoint Dr. Michael HE as a director to fill a vacancy created by Mr. Cheung Kam Cheung's prior resignation. The appointment is accompanied by a director's agreement specifying annual cash compensation of HK$120,000. This is a clear executive appointment event under the taxonomy, material to investors as it affects board composition and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-06
The 6-K discloses the appointment of Guangtong Ren as director and Chief Financial Officer, and the appointment of three independent directors (Jun Ma, YiYun Dai, and Han Tang) with committee assignments, all effective July 1, 2026. While the report also mentions concurrent resignations of four directors/officers, the principal disclosed action is the appointment of new leadership, making exec_appointment the primary classification. This is material as it involves changes to the company's senior financial and governance leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
Marie Washburn appointed as Senior Vice President and Chief Financial Officer effective July 13, 2026, with compensation terms including $340,000 base salary, 45% performance bonus target, and 130,000 RSUs. Dr. Arjun Desai also appointed to the Board as a Class III director on July 2, 2026.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-06
EX-99.1
The press release announces the appointment of Yasunari Harada as Chief Financial Officer and a director of TOYO Co., Ltd, effective July 1, 2026. While the disclosure also mentions the concurrent resignation of the prior CFO, Taewoo "Raymond" Chung, the principal disclosed action is Harada's appointment to a senior executive and board position. The appointment of a CFO with 30+ years of senior leadership experience at major investment banks is material to a reasonable investor's assessment of the company's financial strategy and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Allen C. Harper as Interim Chief Executive Officer and Principal Executive Officer of Rocky Mountain Chocolate Factory, Inc., effective June 29, 2026. While the disclosure also mentions Harper's resignation from his prior CEO role at American Heritage Railways and includes compensatory arrangements ($200,000 in cash and restricted stock units), the principal disclosed action is the appointment to the CEO position. This is a material executive appointment affecting the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
The Item 5.02 disclosure centers on two distinct executive actions: (1) Peter O'Rourke's appointment as President of Quantum Drones (a wholly owned subsidiary) under a new employment agreement with specified compensation (base salary of $20,833.33/month, stock options for 112,859 shares at $1.45/share), and (2) Louis Buffalino's appointment as a director and committee member effective July 1, 2026. While the section also includes compensatory details, the principal disclosed actions are the appointments themselves. The appointment of a President to a material subsidiary and a director to the Board are material governance events affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
Item 5.02
Following the merger closing, Envirotech Vehicles appointed a new executive leadership team effective immediately: Chris Young as CEO and Class II director, Simon Yu as President, Jason Maddox as CFO, and three additional C-suite officers (David Shiue, Gary Chen, and Jenny Yang). Phillip W. Oldridge resigned as Chairman and CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
Paul Carreiro was appointed as President and Chief Executive Officer effective July 6, 2026. The appointment includes compensatory arrangements consisting of LTIP Units and a Retention Agreement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
The filing discloses the appointment of Mark Kelly as Chief Financial Officer effective August 3, 2026, along with the concurrent retirement of interim CFO Gayle Jardine. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a new CFO with detailed background, compensation terms (£165,000 base salary, $40,000 restricted stock grant), and probationary conditions. This is material to investors as CFO changes affect financial oversight and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-06
The 6-K discloses the appointment of Mr. Xu Jiang as a director of DarkIris Inc., effective July 3, 2026, approved by the Board and nominating committee. While the filing also mentions Ms. Hong Yuanfang's resignation, the principal disclosed action is the appointment of a new director (who is also the existing CFO). This is material as it represents a change in board composition and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
The filing discloses the appointment of Joaquin Martin, the Company's Chief Executive Officer of the Americas & Global Vice-Chairman, to the Board of Directors effective July 3, 2026, following recommendation by the Nominating and Corporate Governance Committee. While the filing also mentions the concurrent resignation of Manuel Vizcaino as co-chairman and board member, the principal disclosed action centers on the appointment of an existing senior executive to the board, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 1.01
Item 1.01 discloses the appointment of John Spencer, the Company's Senior Controller, to serve as Chief Financial Officer effective July 1, 2026, along with an Executive Employment Agreement. While Item 5.02(e) also mentions compensatory arrangements (an option award of $25,000), the principal disclosed action in Item 1.01 is the appointment to the CFO role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
The filing discloses the appointment of Scott Gallagher as Interim Chief Financial Officer and W. Scott McBride as Interim Treasurer and Secretary, effective July 1, 2026, following the resignation of Braden Glasbergen as CFO, Treasurer and Secretary on June 30, 2026. While both a departure and appointments occur, the principal disclosed action centers on the appointments of two interim officers to fill critical financial and administrative roles. The appointments are material as they affect the registrant's executive leadership structure and financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-06
Item 5.02
Porfirio Sanchez Talavera was appointed as Chief Executive Officer, Chairman of the Board, and sole member of the Board of Directors on June 29, 2026, replacing Aitan Zacharin who resigned from all officer positions. Sanchez Talavera brings substantial transaction experience with over $2.5 billion in aggregate transaction value.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the election of Carl R. Christenson as a Class A director of Moog Inc., effective July 1, 2026, following an increase in board size from nine to ten directors. This is a clear appointment of a director with significant public company and executive leadership experience (former CEO and Chairman of Altra Industrial Motion Corp., current IDEX board member). Director appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-07-06
Item 5.02
Kathryn M. JohnBull was appointed President and CEO effective July 1, 2026, and Steven V. Oroho, Jr. was appointed Chief Financial Officer and Treasurer effective July 1, 2026. The filing also discloses the retirement of Zachary C. Parker as CEO, with detailed employment agreements and compensation arrangements for the new executives.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
Item 8.01
The filing discloses the appointment of two named executives: Scott David Miller as Product & Analytics Lead (effective July 2, 2026) and Thomas Bennett as Data Science / Modeling Lead (effective July 3, 2026). Both appointments are presented as part of management's strategic expansion of technical capabilities and are material to the company's operational and product development strategy. While the Item 8.01 caption is "Other Events," the substance is clearly executive appointment(s) that strengthen core technical infrastructure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Lynn Seely, M.D. as a new Class III director to AbCellera's Board of Directors effective June 30, 2026. The principal disclosed action is a person taking a governance role. Dr. Seely is an independent director with substantial biopharmaceutical executive experience, including CEO roles at Lyell Immunopharma and Myovant Sciences, and prior board service at Blueprint Medicines (acquired for $9.1 billion). This is a material governance event affecting the composition and expertise of the board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Aleksandr Zhandov as Chief Operating Officer and Deputy Chief Executive Officer effective July 6, 2026. While the disclosure includes employment agreement terms (base salary of $120,000, at-will employment, discretionary bonuses and equity), the principal disclosed action is the appointment of a named executive to a senior officer role reporting to the CEO. This is a material governance event affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-06
Item 5.02
Melissa G. Podruzny was appointed as Interim CFO effective July 1, 2026, following the departure of CFO Joy L. Mbanugo on June 29, 2026. Ms. Podruzny's compensation includes a CAD $141,180 base salary, CAD $30,000 interim premium, CAD $20,000 transition bonus, and a 50,000-share stock option grant with a 24-month vesting schedule.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
The filing discloses the appointment of two individuals, David Gaertner and David Mutina, to the Company's Board of Directors on July 2, 2026. Item 5.02 explicitly covers director appointments, and the prose confirms both individuals were appointed to serve as board members with their qualifications and backgrounds detailed. This is a material governance event affecting the composition of the board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
Shawn P. Payne was elected as a Director and appointed to serve as a member of the Project Risk Committee and chair of the Strategy Committee, effective July 1, 2026, in connection with his previously announced appointment as President and Chief Executive Officer. The principal disclosed action is a person taking on significant leadership roles, making this an executive appointment. This is material as it involves a CEO appointment and board election.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses the appointment of Nicholas Parker as Executive Vice President, Worldwide Field Operations, effective August 24, 2026, along with detailed compensation terms including a $1M base salary, $5M sign-on bonus, and $40M in equity grants. While the section also mentions Ajay K. Puri's retirement, the principal disclosed action centers on Parker's appointment to a senior executive role with material compensation arrangements. This is a significant leadership transition at a major technology company and would affect investor assessment of operational continuity and capital allocation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
The filing announces the appointment of Mr. Botao Shi as interim chief financial officer of Concord Medical, effective June 30, 2026. While the filing also discloses the resignation of the prior CFO, Mr. Wei Jiang, the principal disclosed action is the appointment of a new CFO to fill that role. The appointment of a CFO is a material executive change affecting the registrant's financial leadership and would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
The filing discloses both a director departure (David Sambur's resignation effective July 2, 2026) and a director appointment (Christine Duffy's appointment to fill the vacancy). While both events occur, the principal disclosed action centers on the appointment of Ms. Duffy to the board, with her qualifications, compensation terms, and indemnification agreement detailed. The departure is presented as a mechanical consequence of Apollo Investors' reduced designation rights following their public offering. The appointment of a qualified director with significant hospitality industry experience is the substantive event requiring investor attention.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-02
EX-99.1
The exhibit announces the appointment of Ms. Xiaojing Lu as a director and member of two board committees, effective July 1, 2026. Although the announcement also discloses the concurrent resignation of Ms. Yifang Xu, the principal disclosed action is the appointment of a new director with significant internal operational experience and board committee responsibilities. This is a material governance event affecting board composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-07-02
EX-99.1
The exhibit announces the appointment of Mr. Ying Tian as Chief Financial Officer of iQIYI, effective immediately. This is a material executive appointment to a named officer position (CFO), which would affect a reasonable investor's assessment of the company's financial leadership and governance. The concurrent step-down of Ms. Ying Zeng from Interim CFO is secondary to the principal appointment event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
The disclosure centers on the election of Tali Farhadian Weinstein to the Board of Directors of Consolidated Edison, Inc. and Consolidated Edison Company of New York, Inc., effective July 1, 2026. She was also appointed to two board committees. This is a clear board appointment, which is a material governance event affecting the composition of the registrant's leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-02
Item 5.02
Francis A. Braun III and Dylan G. Petre were appointed to the Board of Directors effective July 1, 2026 upon listing, with Braun designated as Audit Committee chair and Petre appointed to the Nominating and Corporate Governance Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-02
Item 5.02
Michael Blitzer was appointed as director and Chairman of the Board, and Kevin Shannon was appointed as Chief Executive Officer, both effective June 26, 2026, in connection with the Business Combination Agreement with Inflection Point Asset Management LLC.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 83%
filed 2026-07-02
Item 5.02
Dr. Craig Eagle was appointed to OS Therapies' Board of Directors effective June 1, 2026, transitioning from Chief Medical Advisor. Dr. Eagle brings substantial oncology and pharmaceutical leadership experience, including prior roles as CMO at Guardant Health, VP Medical Affairs at Genentech, and senior positions at Pfizer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-02
Item 5.02
The Board appointed Joanna Lohkamp as an interim director, Audit Committee member, and Remuneration Committee chair, effective July 1, 2026. This is a clear executive/board appointment that would materially affect investor assessment of the company's governance and leadership structure, particularly given her committee roles overseeing audit and compensation matters.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-07-02
The filing discloses both the resignation of Mark Pickering as CFO and Executive Officer (effective June 29, 2026) and the appointment of Carrie Rosorea as CFO and Executive Officer on the same date. While both events occur, the principal disclosed action is the appointment of a new CFO to fill the vacancy, making exec_appointment the primary classification. CFO changes are material to investors assessing management continuity and financial oversight.
View raw filing on EDGAR →